Darren J. Schofield, Jennifer Percival-Alwyn, Mateusz Rytelewski, John Hood, Raymond Rothstein, Leslie Wetzel, . . . Michael Oberst. (2021). Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer. Taylor & Francis Group.
Chicago Style (17th ed.) CitationDarren J. Schofield, et al. Activity of Murine Surrogate Antibodies for Durvalumab and Tremelimumab Lacking Effector Function and the Ability to Deplete Regulatory T Cells in Mouse Models of Cancer. Taylor & Francis Group, 2021.
MLA (9th ed.) CitationDarren J. Schofield, et al. Activity of Murine Surrogate Antibodies for Durvalumab and Tremelimumab Lacking Effector Function and the Ability to Deplete Regulatory T Cells in Mouse Models of Cancer. Taylor & Francis Group, 2021.